📰 Transcode Therapeutics News
Page 8 - Transcode Therapeutics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Transcode Therapeutics. Real-time updates on events, politics, business and more.
December 8, 2022
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to a report from Global Market Insights the Breast Cancer Therapeutics Market size, which...
December 8, 2022
PALM BEACH, Fla., Dec. 8, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to a report from Global Market Insights the Breast Cancer Therapeutics Market size, which exceeded
December 7, 2022
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: aureliefrance / Shutterstock.com Hertz (NASDAQ:HTZ) stock is on the ...
November 30, 2022
BOSTON, Nov. 30, 2022 -- TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it has submitted an... | November 30, 2022
November 10, 2022
PALM BEACH, Fla., Nov. 10, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market competition
November 10, 2022
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market...
August 2, 2022
The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode's pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.
August 2, 2022
AbbVie and Sosei add neurological targets in new deal, TransCode and MD Anderson partner on RNA cancer therapies and Xenetic and VolitionRx unite to develop NETs-targeted therapies against cancer.
May 28, 2022
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the recipient of a significant drop in short interest in May. As of May 15th, there was short interest totalling 24,900 shares, a drop of 46.6% from the April 30th total of 46,600 shares. Currently, 0.3% of the shares of the stock are short sold. Based on […]
May 28, 2022
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the recipient of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 24,900 shares, a drop of 46.6% from the April 30th total of 46,600 shares. Currently, 0.3% of the company’s stock are sold short. Based […]